Ownership and insider activity for Fortress Biotech, Inc. (FBIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases).
Price
| Price | $2.46 |
| Market Cap | $82M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-22 | Jin David | A-Award | 400,000 | |
| 2026-04-01 | Jin David | A-Award | 2,967 | $6K |
| 2026-03-18 | ROSENWALD LINDSAY A MD | A-Award | 475,424 | |
| 2026-03-18 | WEISS MICHAEL S | A-Award | 475,424 | |
| 2026-01-01 | Klein Dov | A-Award | 27,322 | |
| 2026-01-01 | Harvey Jimmie | A-Award | 27,322 | |
| 2026-01-01 | Lorenz Kevin | A-Award | 27,322 | |
| 2026-01-01 | Hoenlein Malcolm | A-Award | 27,322 | |
| 2026-01-01 | LOBELL J JAY | A-Award | 27,322 | |
| 2025-10-01 | Jin David | A-Award | 2,711 | $4K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $88.3M | $113.9M | $65.5M | $136.9M | $233.4M | $305.7M | $178.3M | $80.9M | $57.3M | $79.4M |
| Short-term Investments | $3.4M | $39.0M | $17.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $5.2M | $15.2M | $5.5M | $14.4M | $24.7M | $23.8M | $28.3M | $15.4M | $10.4M | $29.9M |
| Inventory | $203000 | $171000 | $678000 | $857000 | $1.4M | $9.9M | $14.2M | $10.2M | $14.4M | $9.6M |
| Total Current Assets | $109.6M | $183.2M | $111.2M | $156.3M | $266.1M | $346.5M | $230.4M | $117.0M | $90.4M | $123.8M |
| Property, Plant & Equipment | $7.4M | $9.5M | $12.0M | $33.9M | $32.4M | $34.1M | $33.0M | $23.5M | $17.1M | $14.8M |
| Goodwill | $18.6M | $18.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $17.4M | $15.2M | $1.4M | $7.4M | $14.6M | $12.6M | $27.2M | $20.3M | $31.9M | $27.6M |
| Total Assets | $170.7M | $245.9M | $141.0M | $226.4M | $333.4M | $396.5M | $294.3M | $167.5M | $144.2M | $185.5M |
| Accounts Payable | $14.2M | $10.0M | $17.9M | $10.1M | $11.4M | $47.4M | $57.2M | $34.8M | $31.6M | $14.2M |
| Short-term Debt | $2.0M | $13.2M | $19.1M | $7.2M | $6.4M | $5.3M | $10.2M | $3.0M | $625000 | 0 |
| Total Current Liabilities | $56.6M | $71.4M | $55.6M | $45.6M | $51.8M | $101.0M | $127.7M | $84.9M | $71.4M | $49.7M |
| Long-term Debt | $26.2M | $49.3M | $60.4M | $82.4M | $59.8M | $46.6M | $93.1M | $60.9M | $58.0M | $59.5M |
| Total Liabilities | $87.8M | $125.4M | $121.2M | $153.9M | $136.4M | $170.6M | $244.3M | $165.9M | $145.9M | $123.4M |
| Retained Earnings | -$245.3M | -$312.1M | -$396.3M | -$436.2M | -$482.8M | -$547.5M | -$634.2M | -$694.9M | -$740.9M | -$734.1M |
| Total Equity | $38.5M | $52.6M | $1.9M | $26.2M | $100.3M | $108.7M | $41.7M | $22.5M | $22.7M | $49.9M |
| Total Debt | $28.2M | $62.5M | $79.5M | $115.1M | $89.1M | $75.0M | $127.3M | $84.7M | $76.0M | $74.3M |
| Net Debt | -$63.5M | -$68.5M | -$3.6M | -$21.7M | -$144.3M | -$230.8M | -$50.9M | $3.7M | $18.7M | -$5.1M |
| Working Capital | $53.1M | $111.7M | $55.6M | $110.6M | $214.4M | $245.4M | $102.7M | $32.1M | $19.0M | $74.1M |
Financial Health
| Debt / Equity | 0.39 |
| Current Ratio | 3.96 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -5.47 |
Profitability
| Return on Equity | 13.66% |
| Return on Invested Capital | -49.97% |
| Return on Assets | 3.67% |
| Gross Margin | 62.53% |
| Operating Margin | -42.86% |
| Net Margin | 163.32% |
Related companies: ADAG · CRVO · GANX · IMUX · NTRB · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of FBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks